secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001108205-23-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis completes FDA-requested enrollment for emavusertib; FY2022 net loss $56.7M
--------------------------------------------------------------------------------

- Completed enrollment of 9 additional patients at 200mg BID for TakeAim Leukemia study ahead of schedule; expects data in Q2, FDA meeting in Q3 for partial clinical hold resolution.
- Net loss for FY2022 was $56.7M ($0.61 per share) vs $45.4M ($0.50) in 2021; Q4 net loss $11.3M ($0.12) vs $13.6M ($0.15) in Q4 2021.
- Revenue from Erivedge royalties was $10.2M in FY2022 vs $10.6M; cash and investments $85.6M as of Dec 31, 2022, expected to fund operations into 2025.
- R&D expenses increased to $43.3M from $34.9M in FY2022; company focused resources on emavusertib development.
- Board adopted amended bylaws including exclusive forum provision and enhanced stockholder nomination requirements; advance notice deadline for 2024 annual meeting changed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/0001108205-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000022/cris-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001108205-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer